FDA warned Celmade over websites selling unapproved, misbranded injectable botulinum toxin products to U.S. consumers.
What happened
FDA reviewed www.celmade.co on August 4, 2026, and celmade.net on September 1, 2026. FDA found the websites offering botulinum toxin type A products, "Wonder tox 100" and "Wondertox 100 Unit," with claims showing they are intended as drugs for human use. FDA said the products lack approved applications and their labeling lacks adequate directions for use.
What FDA found
Celmade offered unapproved new drugs for sale without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))Celmade caused misbranded drugs to be introduced into interstate commerce.
FD&C Act sections 301(a) and 502(f)(1) (21 U.S.C. 331(a), 352(f)(1))The drug labeling failed to bear adequate directions for use.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1)); 21 CFR 201.5The products are prescription drugs that cannot be used safely without a licensed practitioner's supervision.
FD&C Act section 503(b)(1)(A) (21 U.S.C. 353(b)(1)(A))
What FDA wants
FDA asks Celmade to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to send a written response within 15 business days of receipt of the letter. The response should describe corrective steps, steps to prevent recurrence, and include related documentation, referencing MARCS-CMS 735876.
Who should pay attention
- U.S. clinics and med spas that buy injectables
- distributors and wholesalers sourcing botulinum toxin products
- online marketplaces and importers of injectable drugs
This is a summary. Read the original letter on fda.gov.